Suppr超能文献

米力农和硝酸甘油对人体大血管的血管舒张作用可能大于两者相加的效果。

Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries.

作者信息

He G W, Yang C O, Gately H, Furnary A, Swanson J, Ahmad A, Floten S, Wood J, Starr A

机构信息

Albert Starr Academic Center for Cardiac Surgery, St Vincent Hospital and Medical Center, Portland, Oregon, USA.

出版信息

Br J Clin Pharmacol. 1996 Feb;41(2):101-7. doi: 10.1111/j.1365-2125.1996.tb00166.x.

Abstract
  1. The mechanism of vasorelaxation for phosphodiesterase III inhibitors is mediated by increase of cAMP whereas for nitrovasodilators, cGMP. The purpose of this study was to test the hypothesis that the phosphodiesterase III inhibitor milrinone and nitroglycerin (NTG) may have greater than additive effects in human arteries. 2. Internal mammary artery segments (IMA, n = 90) taken from 23 patients were studied in organ chambers. The effect of milrinone (3 microM), NTG (10 nM), or the combination was tested in IMA rings precontracted with potassium (K+, 25 mM) or U46619 (10 nM). Concentration-contraction curves for K+ or U46619 were established in other rings treated with milrinone (70 microM), NTG (0.1 microM), or the combination for 10 min. 3. In K(+)-induced contraction, the combination produced more relaxation (45.4%) than did either milrinone (7.9%, P < 0.05) or NTG (3.8%, P < 0.05) alone. This relaxation was significantly more than the theoretical overadditive effect (P < 0.05). Similar results were seen in U46619-induced contraction (94.1% by the combination vs 70.7% by milrinone, P < 0.05, or 36.1% by NTG, P < 0.05). Pretreatment with the combination depressed contraction to a higher extend compared with milrinone alone (P < 0.05) for the K(+)-induced contraction and to NTG alone (P < 0.05) in U46619-induced contraction. Treatment with the combination also shifted EC50 rightward and this shift was significantly more than that caused by treatment with NTG alone (P < 0.05). 4. We conclude that there is a greater than additive vasorelaxant effect of PDE III inhibitors and nitrovasodilators in human conduit arteries. This effect may be beneficial to patients undergoing coronary artery bypass grafting and to other patients requiring these vasodilators. Reduced doses of the vasodilators in concentration may be sufficient to produce vasodilatation similar to that produced by either of them alone at higher concentrations.
摘要
  1. 磷酸二酯酶III抑制剂的血管舒张机制是通过增加环磷酸腺苷(cAMP)介导的,而硝基血管扩张剂则是通过增加环磷酸鸟苷(cGMP)介导的。本研究的目的是验证以下假设:磷酸二酯酶III抑制剂米力农和硝酸甘油(NTG)在人体动脉中可能具有大于相加的效应。2. 取自23例患者的乳内动脉节段(IMA,n = 90)在器官浴槽中进行研究。在预先用钾离子(K+,25 mM)或U46619(10 nM)预收缩的IMA环中测试米力农(3 microM)、NTG(10 nM)或两者联合使用的效果。在其他用米力农(70 microM)、NTG(0.1 microM)或两者联合处理10分钟的环中建立K+或U46619的浓度-收缩曲线。3. 在K+诱导的收缩中,联合用药产生的舒张作用(45.4%)比单独使用米力农(7.9%,P < 0.05)或NTG(3.8%,P < 0.05)更强。这种舒张作用显著大于理论上的超相加效应(P < 0.05)。在U46619诱导的收缩中也观察到类似结果(联合用药为94.1%,米力农为70.7%,P < 0.05;NTG为36.1%,P < 0.05)。对于K+诱导的收缩,与单独使用米力农相比(P < 0.05),联合用药预处理使收缩抑制程度更高;对于U46619诱导的收缩,与单独使用NTG相比(P < 0.05),联合用药预处理使收缩抑制程度更高。联合用药处理还使半数有效浓度(EC50)右移,且这种右移显著大于单独使用NTG引起的右移(P < 0.05)。4. 我们得出结论,磷酸二酯酶III抑制剂和硝基血管扩张剂在人体传导动脉中具有大于相加的血管舒张作用。这种作用可能对接受冠状动脉旁路移植术的患者以及其他需要这些血管扩张剂的患者有益。降低血管扩张剂的浓度剂量可能足以产生与单独使用较高浓度的其中任何一种药物时相似的血管舒张作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验